دورية أكاديمية
أعرض في EDS

Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

التفاصيل البيبلوغرافية
العنوان: Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.
المؤلفون: FakhriRavari A; Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda CA, USA., Simiyu B; Department of Pharmacy Services, West Jefferson Medical Center, Marrero, LA, USA., Morrisette T; Department of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC, USA.; Department of Pharmacy Services, Medical University of South Carolina Shawn Jenkins Children's Hospital, Charleston, SC, USA., Dayo Y; Department of System Pharmacy Services, Ochsner Health, New Orleans, LA, USA., Abdul-Mutakabbir JC; Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda CA, USA.; Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA, USA.
المصدر: Drugs in context [Drugs Context] 2022 Jan 20; Vol. 11. Date of Electronic Publication: 2022 Jan 20 (Print Publication: 2022).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Bioexcel Publishing Ltd Country of Publication: England NLM ID: 101262187 Publication Model: eCollection Cited Medium: Print ISSN: 1745-1981 (Print) Linking ISSN: 17404398 NLM ISO Abbreviation: Drugs Context Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2016- : London : Bioexcel Publishing Ltd.
Original Publication: Long Hanborough, Oxon : CSF Medical Communications, c2005-
مستخلص: Antimicrobial resistance is a global public health threat due to its associated increase in mortality, and the most appropriate treatment algorithms for resistant and persistent Gram-positive and Gram-negative infections have yet to be elucidated. Whilst combination therapy has been touted as a viable method to overcome prominent resistant mechanisms represented amongst these microbes, the optimal agents to utilize remains controversial. Beta-lactams have a safe profile and are bactericidal against most Gram-positive and Gram-negative microorganisms. Thus, the use of dual beta-lactam therapy to overcome multidrug-resistant pathogens is of supreme interest. This article reviews the mechanisms of beta-lactam resistance in Gram-positive and Gram-negative bacteria, discusses the rationale for dual beta-lactam use against multidrug-resistant infections (and other scenarios in which this strategy may be most utilized in clinical practice), explores the available in vitro, in vivo and clinical data, and provides considerations for the use of dual beta-lactam therapy against Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii pathogens.
Competing Interests: Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/12/dic.2021-8-9-COI.pdf
(Copyright © 2022 FakhriRavari A, Simiyu B, Morrisette T, Dayo Y, Abdul-Mutakabbir JC.)
References: Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28630191)
BMC Infect Dis. 2011 Oct 19;11:279. (PMID: 22011388)
Antimicrob Agents Chemother. 2009 Aug;53(8):3365-70. (PMID: 19506063)
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6609-6618. (PMID: 27572414)
Antimicrob Agents Chemother. 1999 Sep;43(9):2103-8. (PMID: 10471548)
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3178-82. (PMID: 26926624)
Mikrobiyol Bul. 2014 Apr;48(2):311-5. (PMID: 24819268)
BMC Infect Dis. 2020 Jun 11;20(1):408. (PMID: 32527246)
Antimicrob Agents Chemother. 1997 May;41(5):1158-61. (PMID: 9145889)
Heart. 1997 Apr;77(4):380-3. (PMID: 9155624)
Antimicrob Agents Chemother. 2013 May;57(5):2388-90. (PMID: 23439635)
Microb Drug Resist. 2018 Mar;24(2):199-202. (PMID: 28708458)
Heart. 1997 Mar;77(3):260-3. (PMID: 9093046)
Am J Health Syst Pharm. 2019 Sep 3;76(18):1383-1394. (PMID: 31505562)
J Antimicrob Chemother. 2015 Aug;70(8):2414-7. (PMID: 25953804)
Antimicrob Agents Chemother. 2015 Nov 09;60(1):669-73. (PMID: 26552970)
Tex Heart Inst J. 2016 Oct 1;43(5):453-457. (PMID: 27777535)
Antimicrob Agents Chemother. 1984 Feb;25(2):212-5. (PMID: 6538772)
Lancet Infect Dis. 2013 Dec;13(12):1057-98. (PMID: 24252483)
J Am Chem Soc. 2015 Jan 14;137(1):190-200. (PMID: 25495032)
Antimicrob Agents Chemother. 2015 Oct;59(10):5903-8. (PMID: 26386029)
Clin Infect Dis. 2002 Jan 15;34(2):159-66. (PMID: 11740702)
Molecules. 2020 Mar 16;25(6):. (PMID: 32187986)
Antimicrob Agents Chemother. 2008 Mar;52(3):995-1000. (PMID: 18086837)
Antimicrob Agents Chemother. 2018 Nov 26;62(12):. (PMID: 30249690)
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents. (PMID: 17630334)
Antimicrob Agents Chemother. 2017 Mar 24;61(4):. (PMID: 28096164)
Drugs. 2018 Jan;78(1):65-98. (PMID: 29230684)
Can J Infect Dis. 1995 Jan;6(1):21-7. (PMID: 22514377)
Int J Antimicrob Agents. 2018 Mar;51(3):468-478. (PMID: 29337066)
Nat Chem Biol. 2015 Nov;11(11):855-61. (PMID: 26368589)
Antimicrob Agents Chemother. 2020 Apr 21;64(5):. (PMID: 32094127)
Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa064. (PMID: 32190711)
Antimicrob Agents Chemother. 2014;58(2):1195-9. (PMID: 24247139)
Nature. 2018 Jul;559(7713):259-263. (PMID: 29973719)
Med Lett Drugs Ther. 1987 Aug 28;29(747):79-81. (PMID: 3039328)
Curr Infect Dis Rep. 2014 Oct;16(10):431. (PMID: 25165018)
Antimicrob Agents Chemother. 2018 Apr 26;62(5):. (PMID: 29530842)
Clin Microbiol Infect. 2016 Feb;22(2):147-153. (PMID: 26409059)
J Antimicrob Chemother. 2003 Sep;52(3):514-7. (PMID: 12917251)
J Antimicrob Chemother. 1995 Jan;35(1):75-84. (PMID: 7768785)
Antimicrob Agents Chemother. 1995 Sep;39(9):1984-7. (PMID: 8540703)
Kaohsiung J Med Sci. 2004 Jun;20(6):261-7. (PMID: 15253466)
Clin Infect Dis. 2009 May 15;48 Suppl 4:S254-9. (PMID: 19374581)
Antimicrob Agents Chemother. 1984 Feb;25(2):283-5. (PMID: 6538773)
Antimicrob Agents Chemother. 2013 Jun;57(6):2900-1. (PMID: 23571536)
J Infect. 2015 Mar;70(3):309-11. (PMID: 25305144)
Diagn Microbiol Infect Dis. 2014 Dec;80(4):239-59. (PMID: 25308565)
Lancet Infect Dis. 2014 Sep;14(9):813-9. (PMID: 25104307)
J Antimicrob Chemother. 2015 Jul;70(7):2133-43. (PMID: 25900159)
J Infect Dis. 2004 Dec 15;190(12):2162-6. (PMID: 15551215)
Drug Resist Updat. 2011 Apr;14(2):118-24. (PMID: 21435939)
Sci Rep. 2018 May 8;8(1):7237. (PMID: 29740150)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28630192)
Emerg Infect Dis. 2007 Dec;13(12):1840-6. (PMID: 18258033)
IDCases. 2017 Jun 15;9:53-55. (PMID: 28660131)
BMJ. 2003 May 24;326(7399):1111. (PMID: 12763980)
Antimicrob Agents Chemother. 2009 Nov;53(11):4580-7. (PMID: 19506057)
Crit Care. 2008;12 Suppl 4:S3. (PMID: 18495060)
Cold Spring Harb Perspect Med. 2016 May 02;6(5):. (PMID: 27091943)
mBio. 2013 Aug 20;4(4):. (PMID: 23963180)
Infect Drug Resist. 2018 Aug 07;11:1083-1095. (PMID: 30122965)
Arch Intern Med. 2009 Mar 9;169(5):463-73. (PMID: 19273776)
Ann Pharmacother. 2000 May;34(5):656-61. (PMID: 10852095)
Antimicrob Agents Chemother. 2019 Jun 24;63(7):. (PMID: 30988147)
Ann Intensive Care. 2015 Dec;5(1):61. (PMID: 26261001)
Antimicrob Agents Chemother. 2008 Apr;52(4):1510-2. (PMID: 18250190)
Int J Infect Dis. 2015 Apr;33:132-4. (PMID: 25597275)
Rev Infect Dis. 1988 May-Jun;10(3):616-23. (PMID: 3293164)
J Clin Microbiol. 2007 Aug;45(8):2723-5. (PMID: 17581941)
N Engl J Med. 2011 May 26;364(21):2016-25. (PMID: 21612470)
Antimicrob Agents Chemother. 2011 Jun;55(6):3002-4. (PMID: 21422205)
PLoS One. 2011;6(8):e23287. (PMID: 21829724)
Antimicrob Agents Chemother. 2015 Jul;59(7):3925-34. (PMID: 25896695)
Clin Microbiol Infect. 2004 Jan;10(1):84-5. (PMID: 14706093)
Clin Infect Dis. 2004 Nov 1;39(9):1267-84. (PMID: 15494903)
J Comp Eff Res. 2018 Sep;7(9):901-911. (PMID: 30192166)
Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1211-20. (PMID: 23553594)
Antimicrob Agents Chemother. 2019 Apr 25;63(5):. (PMID: 30858212)
Circulation. 2015 Oct 13;132(15):1435-86. (PMID: 26373316)
Clin Infect Dis. 2020 Mar 3;70(6):1263-1264. (PMID: 31260045)
Drugs. 1987 Jun;33(6):577-609. (PMID: 3038500)
Curr Opin Infect Dis. 2008 Aug;21(4):367-71. (PMID: 18594288)
Antimicrob Agents Chemother. 1999 Mar;43(3):639-46. (PMID: 10049280)
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1305-1315. (PMID: 28210888)
J Antimicrob Chemother. 2014 Jun;69(6):1718-20. (PMID: 24521856)
Case Rep Infect Dis. 2017;2017:8096420. (PMID: 28815094)
Clin Infect Dis. 2004 Aug 1;39(3):309-17. (PMID: 15306996)
Rev Esp Quimioter. 2019 Oct;32(5):465-468. (PMID: 31515975)
Ann Intern Med. 2007 Apr 17;146(8):574-9. (PMID: 17438316)
Antimicrob Agents Chemother. 2018 Sep 24;62(10):. (PMID: 30061284)
Sci Rep. 2019 Jun 24;9(1):9098. (PMID: 31235728)
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. (PMID: 27432599)
J Antimicrob Chemother. 2020 Sep 1;75(9):2622-2632. (PMID: 32464664)
Curr Protein Pept Sci. 2009 Oct;10(5):397-400. (PMID: 19538149)
Core Evid. 2014 Jan 24;9:13-25. (PMID: 24493994)
Antimicrob Agents Chemother. 2020 Jun 23;64(7):. (PMID: 32312776)
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0264620. (PMID: 34125590)
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. (PMID: 29272413)
J Antimicrob Chemother. 2018 Feb 1;73(2):542-544. (PMID: 29165563)
Medchemcomm. 2018 Aug 17;9(9):1439-1456. (PMID: 30288219)
Clin Infect Dis. 1992 Sep;15(3):486-9. (PMID: 1520798)
Am J Med. 1986 May 30;80(5C):21-9. (PMID: 3487247)
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878. (PMID: 32427286)
Int J Infect Dis. 2020 Aug;97:11-18. (PMID: 32473388)
Open Forum Infect Dis. 2021 May 23;8(7):ofab261. (PMID: 34258313)
Trends Microbiol. 2006 Sep;14(9):413-20. (PMID: 16876996)
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2849-57. (PMID: 26926635)
Clin Infect Dis. 2020 Sep 12;71(6):1413-1418. (PMID: 31773134)
Molecules. 2020 Jun 23;25(12):. (PMID: 32586045)
J Antimicrob Chemother. 2010 Jul;65(7):1540-2. (PMID: 20435778)
Antimicrob Agents Chemother. 2017 Mar 24;61(4):. (PMID: 28167541)
Antimicrob Resist Infect Control. 2016 Nov 16;5:44. (PMID: 27895902)
Transpl Infect Dis. 2018 Feb;20(1):. (PMID: 29064133)
Diagn Microbiol Infect Dis. 2007 Jun;58(2):163-70. (PMID: 17368801)
Antibiotics (Basel). 2021 Jul 20;10(7):. (PMID: 34356801)
J Infect Dis. 2004 Mar 15;189(6):1113-8. (PMID: 14999616)
Infection. 1991;19 Suppl 4:S229-33. (PMID: 1879958)
Clin Infect Dis. 2013 May;56(9):1261-8. (PMID: 23392394)
Braz J Infect Dis. 2018 May - Jun;22(3):235-238. (PMID: 29806996)
Crit Care. 2010;14(3):224. (PMID: 20594363)
Int J Antimicrob Agents. 2006 Nov;28(5):454-6. (PMID: 16987639)
Antimicrob Agents Chemother. 2019 Jul 25;63(8):. (PMID: 31182535)
Antimicrob Agents Chemother. 2017 Dec 21;62(1):. (PMID: 29061741)
فهرسة مساهمة: Keywords: Gram-negative; Gram-positive; antimicrobial resistance; beta-lactam; combination therapy; double carbapenem therapy; dual therapy
تواريخ الأحداث: Date Created: 20220211 Latest Revision: 20220212
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8798368
DOI: 10.7573/dic.2021-8-9
PMID: 35145558
قاعدة البيانات: MEDLINE
الوصف
تدمد:1745-1981
DOI:10.7573/dic.2021-8-9